RETINITIS PIGMENTOSA

This study looks at the long-term safety of an antioxidant called N-Acetylcysteine (NAC) in 30 adults with retinitis pigmentosa, a disease that causes gradual vision loss and blindness. Participants take NAC tablets twice a day for up to 12 months. The goal is to see if NAC is sa…

This early-stage study tests a single injection of RTx-015 into the eye for people with retinitis pigmentosa or choroideremia, two inherited conditions that cause progressive vision loss. About 18 adults will receive one of four doses and be monitored for 5 years to check safety …

This early-stage study tests whether it is safe to inject a person's own bone marrow stem cells into their eye to treat blindness caused by retinal diseases like macular degeneration and diabetic retinopathy. Fifteen adults with severe vision loss will receive one injection and b…

This study tests a gene therapy for a rare inherited eye disease called X-linked retinitis pigmentosa, which causes gradual vision loss. The treatment uses a harmless virus to deliver a working gene to the retina. The study includes 4 Japanese participants aged 5 or older and foc…

This phase 3 trial tests whether an oral antioxidant called N-acetylcysteine (NAC) can slow the loss of vision in people with retinitis pigmentosa, an inherited eye disease that causes night blindness and tunnel vision. About 485 adults aged 18 to 65 will take NAC or a placebo da…

This program offers up to 75 adults with retinitis pigmentosa access to an experimental treatment called OCU400. It is for people who cannot join the main Phase 3 study and have no other FDA-approved options. The goal is to provide treatment while gathering more safety and effect…

This study tests a gene therapy called OCU400 for people with retinitis pigmentosa, an eye disease that causes vision loss. The treatment is injected under the retina to help slow or improve vision. The trial enrolled 140 people aged 3 and older and measures how well they can nav…

This study tests a new drug called OCT-980 for people with a genetic form of retinitis pigmentosa, an eye disease that leads to vision loss. The trial first checks safety in healthy volunteers, then tests the drug in patients to see if it can slow or stop the disease. About 32 pe…

This study tests a new gene therapy, CPK850, for people with a rare inherited eye disease called RLBP1 retinitis pigmentosa, which causes progressive vision loss and trouble seeing in the dark. The treatment is given as a single injection under the retina to deliver a working cop…

This study looks at whether a mild electrical current applied to the eye can improve vision in people with retinitis pigmentosa, a genetic condition that causes gradual vision loss. Twenty-one adults with the disease will receive the treatment and have their vision tested over se…

This study follows 44 people with a rare genetic eye condition caused by PCDH15 mutations to see how their vision changes over time. Researchers measure things like visual field, sharpness, and retinal structure. The goal is not to treat the disease but to learn how it progresses…

This study follows 50 people with a rare inherited eye condition called PRPF31-related retinal dystrophy (RP11) to understand how their vision and quality of life change over time. Participants undergo various eye tests and questionnaires, but no experimental treatment is given. …

This study follows 12 adults with severe retinitis pigmentosa, a genetic eye disease that causes vision loss, to see which vision tests work best for them and how quickly their sight declines over a year. Participants will not receive any treatment—the goal is to better understan…

This study looks at new methods to measure vision and eye health in people with a genetic eye disease called retinitis pigmentosa. Researchers will use advanced imaging and vision tests to see how the disease changes over time. The goal is to find the best ways to track the disea…

This study follows 103 adults with retinitis pigmentosa caused by EYS gene mutations to measure how their vision changes over 4 years. Researchers track things like visual field, sharpness, and retinal structure. The goal is to find the best ways to measure disease progression, w…